Linvoseltamab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 29, 2026

The clinical evidence base for Linvoseltamab comprises 3 peer-reviewed publications across 3 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Multiple Myeloma. Most recent publication: Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses., Clin Lymphoma Myeloma Leuk, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.
Lee HC, Zonder JA, Dhodapkar MV, et al. · Clin Lymphoma Myeloma Leuk · 2026
PubMed: PMID 41387038 · NCT03761108 (LINKER-MM1) · Multiple Myeloma
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Bumma N, Richter J, Jagannath S, et al. · J Clin Oncol · 2024
PubMed: PMID 38879802 · NCT03761108 (LINKER-MM1) · Multiple Myeloma
Dose optimisation to improve access to effective cancer medicines.
Tannock IF, de Vries EGE, Fojo A, et al. · Lancet Oncol · 2025
PubMed: PMID 40049207 · NCT07474961 (BLOOD-dose) · Multiple Myeloma

Publications by year

2024–2026: 3 publications.

2024

2025

2026

Publications by indication

Multiple Myeloma (3)

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.
Clin Lymphoma Myeloma Leuk · 2026 · PMID 41387038 · NCT03761108
Dose optimisation to improve access to effective cancer medicines.
Lancet Oncol · 2025 · PMID 40049207 · NCT07474961
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
J Clin Oncol · 2024 · PMID 38879802 · NCT03761108

Publications by journal

Clin Lymphoma Myeloma Leuk1 paper
J Clin Oncol1 paper
Lancet Oncol1 paper

All Linvoseltamab publications (3)

2026 (1 paper)

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.
Lee HC, Zonder JA, Dhodapkar MV, et al. · Clin Lymphoma Myeloma Leuk · 2026 · Derived
PubMed: PMID 41387038 · NCT03761108 (LINKER-MM1) · Multiple Myeloma

2025 (1 paper)

Dose optimisation to improve access to effective cancer medicines.
Tannock IF, de Vries EGE, Fojo A, et al. · Lancet Oncol · 2025 · Background
PubMed: PMID 40049207 · NCT07474961 (BLOOD-dose) · Multiple Myeloma

2024 (1 paper)

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Bumma N, Richter J, Jagannath S, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 38879802 · NCT03761108 (LINKER-MM1) · Multiple Myeloma

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Fri, 29 May 2026 17:29:29 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).